Here, we found VEGFR2 was significantly up‐regulated during the establishment of lenvatinib resistance in HepG2 and Huh7 cells, indicating VEGFR2 could also be a predicator of the efficacy of lenvatinib against HCC. The gene discussed is KDR; the disease is hepatocellular carcinoma.